Icaritin
Sponsors
Chinese Academy of Medical Sciences, Beijing Shenogen Biomedical Co., Ltd, Henan Cancer Hospital, Sir Run Run Shaw Hospital, Nanjing Tianyinshan Hospital
Conditions
Advanced HBV-Related Hepatocellular Carcinoma (HCC)Advanced Pancreatic Ductal AdenocarcinomaHCCHepatocellular CarcinomaHepatocellular Carcinoma (HCC)Hepatocellular Carcinoma(HCC)Metastatic Breast CancerSolid Tumors
Phase 1
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients
NCT01278810
Start: 2010-11-30End: 2011-12-31Target: 30Updated: 2011-01-28
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors
CompletedNCT02496949
Start: 2011-11-30End: 2013-08-31Updated: 2015-07-14
Phase 2
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
CompletedNCT01972672
Start: 2013-10-31End: 2017-03-31Updated: 2021-01-27
Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients
NCT06285149
Start: 2024-03-01End: 2025-06-01Target: 80Updated: 2024-02-29
Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
RecruitingNCT06825546
Start: 2025-04-01End: 2027-10-01Target: 70Updated: 2025-06-27
Phase 3
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
TerminatedNCT03236649
Start: 2017-09-20End: 2022-02-08Updated: 2023-02-08
The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
NCT03236636
Start: 2017-09-08End: 2022-12-30Target: 312Updated: 2021-01-27
Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
RecruitingNCT05594927
Start: 2022-12-12End: 2025-08-30Target: 261Updated: 2024-08-07